A Phase 2 interventional study of High frequency repetitive transcranial magnetic stimulation and Sham repetitive transcranial magnetic stimulation in Stroke, Stroke, Chronic and Fatigue, sponsored by VA Office of Research and Development. Recruiting at 2 sites in United States. Open to participants aged 34 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Stroke by VA Office of Research and Development — 13 open to participants now, 17 under way, none of them phase 3. Stroke · VA Office of Research and Development.
Among the 87 studies in Stroke by VA Office of Research and Development, this one is the 22nd largest by planned enrollment of the 79 interventional ones that give a count, is one of 4 that started in 2023, is one of 4 in phase 2, reaches primary completion later than 13 of the 16 other live ones, and was the 78th registered.
8,258 studies on the registry are indexed under Stroke; 2,055 are open to participants now.
Browse Stroke studies →13 of the 87 studies in Stroke by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 40–80
VA Office of Research and Development · Sites in United States
Ages 21+
VA Office of Research and Development · Sites in United States
Ages 18–80
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 40–80
By country, each count listing its studies:
Of the 1,415 Stroke studies recruiting now, 695 (49%) set no upper age limit and 280 (20%) stop at 75 or younger; 77 take children under 18; 195 take healthy volunteers.
This study: 34 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 1
First in 1999; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 49 across 6,027 interventional studies indexed under Stroke.
Median enrollment 38 across the 79 interventional studies, 56 across the 8 observational. Of the 67 that completed or were terminated, 60 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
VA Office of Research and Development is the lead sponsor of 1,771 studies on the registry; 392 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
9 of the studies in Stroke by VA Office of Research and Development that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06400186VA Office of Research and DevelopmentMovement Amplification Gait Training to Enhance Walking Balance Post-Stroke | 2026-12-31 |
| NCT05983185VA Office of Research and DevelopmentPrism Adaptation Therapy (PAT) for Right Brain Stroke Rehabilitation | 2026-12-31 |
| NCT05760885VA Office of Research and DevelopmentMultisensory Augmentation for Post-stroke Standing Balance | 2027-01-01 |
| NCT05628324VA Office of Research and DevelopmentEMG-Controlled Game to Retrain Upper Extremity Muscle Activation Patterns Following Stroke | 2027-03-31 |
| NCT05296408VA Office of Research and DevelopmentExoskeleton Research: Myoelectric Orthosis for Rehab of Severe Chronic Arm Motor Deficits | 2027-04-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 87 studies in Stroke by VA Office of Research and Development, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This experimental trial is investigating the use of magnetic stimulation of the brain as a possible treatment for post-stroke fatigue in people who have had a stroke more than six months prior to enrolling. Fatigue is a common condition after a stroke and can negatively impact an individual's ability to perform desired social and physical activities. Magnetic stimulation of the brain has been shown to improve signs and symptoms of related psychological (e.g., depression) conditions. Participants in this trial will receive a type of magnetic stimulation called repetitive transcranial magnetic stimulation, or rTMS. The investigators will measure feelings of fatigue and other clinical characteristics related to mood and cognition before and after participants receive rTMS.
The PI for this trial transferred to the Atlanta VA Medical Center in Feb 2026. As a result, the trial was suspended at the original site and moved to the Atlanta area. Additional changes accompanying the site transfer include removing one arm of the study (an active comparator), leaving two arms: one with the active treatment and the other with a sham treatment. Eligibility criteria were also updated to be more ecologically relevant. Ethical approvals for the new site, Atlanta, were provided by the Emory University IRB.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomly assigned to receive high-frequency repetitive transcranial magnetic stimulation (rTMS) to the top of their head for approximately 40 minutes.
Device: High frequency repetitive transcranial magnetic stimulation
Participants will be randomly assigned to receive sham/placebo repetitive transcranial magnetic stimulation (rTMS) to the their head for approximately 40 minutes. This is a control condition.
Device: Sham repetitive transcranial magnetic stimulation
MagVenture MagPro X100 with MagOption
MagVenture MagPro X100 with MagOption
Change in Fatigue Severity Scale (FSS) score
The Fatigue Severity Scale (FSS) is a patient reported outcome measure assessing perceived influence of fatigue over the past week. The scale consists of nine questions measured on a 7-point Likert scale (1-7). The FSS' range of scores is from 9 (min) to 63 (max) with lower numbers representing lower/less impact of fatigue.
Time frame: Change from baseline FSS score to 7 days after last treatment
Change in Modified Fatigue Impact Scale (MFIS) score
The Modified Fatigue Impact Scale (MFIS) is a Patient reported outcome assessing the impact of fatigue over the past four weeks. The questionnaire is comprised of 21 questions covering three domains (physical, cognitive, and psychosocial subscales). The assessment is graded on a 5 point Likert scale (0-4). The MFIS' range of scores is from 0-84 with higher scores indicating greater impact/worse fatigue. The range of scores for the physical, cognitive, and psychosocial subscales are 0-36, 0-40, and 0-8 respectively. Greater scores indicate greater/worse impact of fatigue.
Time frame: Change from baseline MFIS score to 7 Days after last treatment
Change in Fatigue Severity Scale (FSS) score
The Fatigue Severity Scale (FSS) is a patient reported outcome measure assessing perceived influence of fatigue over the past week. The scale consists of nine questions measured on a 7-point Likert scale (1-7). The FSS' range of scores is from 9 (min) to 63 (max) with lower numbers representing lower/less impact of fatigue.
Time frame: Change from baseline FSS score to 3 months after last treatment
Change in Modified Fatigue Impact Scale (MFIS) score
The Modified Fatigue Impact Scale (MFIS) is a Patient reported outcome assessing the impact of fatigue over the past four weeks. The questionnaire is comprised of 21 questions covering three domains (physical, cognitive, and psychosocial subscales). The assessment is graded on a 5 point Likert scale (0-4). The MFIS' range of scores is from 0-84 with higher scores indicating greater impact/worse fatigue. The range of scores for the physical, cognitive, and psychosocial subscales are 0-36, 0-40, and 0-8 respectively. Greater scores indicate greater/worse impact of fatigue.
Time frame: Change from baseline MFIS score to 3 months after last treatment
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for Oct 2027, 54 months after the start.
Of 113 non-industry phase 2 interventional studies under Stroke, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 54 months is above that.
Counting every sponsor, half of 133 studies reached it within 40 months; a quarter within 24 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VA Office of Research and Development →